B-NHL

8 registered clinical trials studyying B-NHL — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06689917	Tongji Hospital	N/A
Recruiting	Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL NCT06695013	Ruijin Hospital	Phase 2
Recruiting	JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia NCT06678282	Shenzhen Genocury Biotech Co., Ltd.	N/A
Recruiting	CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R NCT05442515	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	An Evaluation of LY007 Cell Injection for r/r B-NHL NCT06279611	Shanghai Longyao Biotechnology Inc., Ltd.	Phase 1
Recruiting	An Evaluation of LY007 Cell Injection for r/r B-NHL NCT06364852	Ruijin Hospital	Phase 1
Completed	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD NCT03448393	National Cancer Institute (NCI)	Phase 1
Completed	Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing NCT02315612	National Cancer Institute (NCI)	Phase 1